Page 137 - 2020_09-Haematologica-web

DA-EPOCH-R/HD-MTX for CD5+ DLBCL
30. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-3902.
31. Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-1052.
32. Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511-2516.
33. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Cancer Discov. 2017;7(9):1018-1029.
34. Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lym-
phoma. Blood. 2019;133(5):436-445.
35. Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intra- venous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multi- center prospective 'proof of concept' phase II study of the French Oculo-Cerebral lym- phoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol. 2019;
30(4):621-628.
36. Ferreri AJM, Calimeri T, Conte GM, et al. R-
CHOP preceded by blood-brain barrier per- meabilization with engineered tumor necro- sis factor-alpha in primary CNS lymphoma. Blood. 2019;134(3):252-262.
37. Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index
improves CNS relapse prediction in DLBCL.
Blood. 2019;133(9):919-926.
38. Vitolo U, Chiappella A, Ferreri AJ, et al. First-
line treatment for primary testicular diffuse large B-cell lymphoma with rituximab- CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an interna- tional phase II trial. J Clin Oncol. 2011;29(20):2766-2772.
39. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360- 3365.
40. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, pred- nisone, vincristine, cyclophosphamide, dox- orubicin, and rituximab) in untreated aggres- sive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multi- centre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609-e617.
haematologica | 2020; 105(9)
2315